Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With Hypertension

Authors:
  • TGThe Valsartan Pediatric Hypertension Study Group
    The Valsartan Pediatric Hypertension Study Group

Abstract
The effectiveness and safety of valsartan have not been assessed in hypertensive children. Therefore, hypertensive patients aged 6 to 16 years (n=261) were randomized to receive weight‐stratified low‐ (10/20 mg), medium‐ (40/80 mg), or high‐dose (80/160 mg) valsartan for 2 weeks. After 2 weeks, patients were randomized to a 2‐week placebo‐controlled withdrawal phase. Dose‐dependent reductions in sitting systolic blood pressure (SSBP) and sitting diastolic blood pressure (SDBP) were observed after 2 weeks (low dose, −7.9/−4.6 mm Hg; medium dose, −9.6/−5.8 mm Hg; high dose, −11.5/−7.4 mm Hg [P<.0001 for all groups]). During the withdrawal phase, SSBP and SDBP were both lower in the pooled valsartan group than in the pooled placebo group (SSBP, −2.7 mm Hg [P=.0368]; SDBP, −3.0 mm Hg [P=.0047]). Similar efficacy was observed in all subgroups. Valsartan was well tolerated and headache was the most commonly observed adverse event during both the double‐blind and 52‐week open‐label phases. J Clin Hypertens (Greenwich). 2011;13:357–365. ©2011 Wiley Periodicals, Inc.

This publication has 31 references indexed in Scilit: